Showing results (221-230 of 424) with videos related to
Sort By:
Pageof 43
Hepatology (Baltimore, Md.)|November 27, 2004
Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposureVincent Di Martino, Pascal Lebray, Robert P Myers, et al.Nature Metabolism|April 10, 2023
A proteo-transcriptomic map of non-alcoholic fatty liver disease signaturesOlivier Govaere, Megan Hasoon, Leigh Alexander, et al.Hepatology (Baltimore, Md.)|December 19, 2023
Artificial intelligence scoring of liver biopsies in a phase II trial of semaglutide in nonalcoholic steatohepatitisVlad Ratziu, Sven Francque, Cynthia A Behling, et al.The Lancet. Gastroenterology & Hepatology|September 24, 2021
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a studyKenneth Cusi, Naim Alkhouri, Stephen A Harrison, et al.Journal of Internal Medicine|May 13, 2024
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trialsFaiez Zannad, Arun J Sanyal, Javed Butler, et al.Journal of Hepatology|April 14, 2010
Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferredArnaud Galbois, Marika Rudler, Julien Massard, et al.Gastroenterologie Clinique Et Biologique|July 10, 2004
Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteriaGilles Bommelaer, Thierry Poynard, Claude Le Pen, et al.Gastroenterologie Clinique Et Biologique|March 28, 2006
Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQOL)Michel Amouretti, Claude Le Pen, Anne-Françoise Gaudin, et al.Journal of Hepatology|December 7, 2023
NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trialsVlad Ratziu, Stephen A Harrison, Yacine Hajji, et al.Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2024
No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCCFrancisca-Dora Copil, Claudia Campani, Marie Lequoy, et al.Pageof 43